Ono Pharmaceutical Co. (OTCMKTS:OPHLF – Get Free Report) shares gapped down before the market opened on Monday . The stock had previously closed at $14.94, but opened at $14.15. Ono Pharmaceutical shares last traded at $14.15, with a volume of 200 shares changing hands.
Analyst Ratings Changes
Separately, Zacks Research lowered Ono Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research report on Friday, September 4th. One research analyst has rated the stock with a Hold rating, According to data from MarketBeat.com, the stock presently has an average rating of “Hold”.
View Our Latest Report on OPHLF
Ono Pharmaceutical Stock Performance
About Ono Pharmaceutical
Ono Pharmaceutical Co, Ltd. is a Japanese research-driven pharmaceutical company headquartered in Osaka. The company discovers, develops, manufactures and markets prescription medicines, with a focus on oncology, immunology, neurology and other specialty-care areas. Its activities include both internally developed products and collaborations with pharmaceutical and biotechnology companies worldwide.
Ono is best known internationally for Opdivo (nivolumab), an immune checkpoint inhibitor developed in collaboration with Bristol Myers Squibb and used to treat multiple types of cancer.
See Also
- Five stocks we like better than Ono Pharmaceutical
- Meta’s Muse Highlights Arm’s Growing Role in AI Infrastructure
- Oura’s $15.6 Billion IPO Is Betting Investors See More Than a Smart Ring
- AMD Chips Away at NVIDIA’s AI Throne
- Is the Fed Playing Chess With Rates—Or Just Behind the Curve Again?
Receive News & Ratings for Ono Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ono Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
